CTOs on the Move

VAYA Pharma

www.vayapharma.com

 
At VAYA Pharma, we are committed to improving quality of life and delivering products that exemplify our key values. VAYA Pharma`s history of clinical research is based on understanding the potential of the human body in order to reform medicine. Through this research, we have discovered a strong correlation between certain disorders and lipid imbalances in affected individuals. Because of this, VAYA Pharma focuses on developing innovations for the clinical dietary management of disorders that are specifically associated with lipid imbalances. Our products deliver a nutritional based solution that are familiar to the human body and clinically proven to be ...
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.vayapharma.com
  • 800 West Baltimore Street Ste. 100
    Baltimore, MD USA 21201
  • Phone: 410.297.0020

Executives

Name Title Contact Details

Similar Companies

Immune Control

Immune Control is a West Conshohocken, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CuraPharm Inc

CuraPharm Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kezar Life Sciences

Kezar co-founder Christopher Kirk, Ph.D. began his work on the unique function of the immunoproteasome at Proteolix in 2005, while working on the compound that would become the successful multiple myeloma drug KYPROLIS™ (carfilzomib). As VP of Research at Onyx Pharmaceuticals, which acquired Proteolix in 2009, Christopher led the efforts to develop the first selective inhibitors of the immunoproteasome and designed multiple studies demonstrating their profound immunomodulatory effects. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergies between protein degradation and protein secretion, two fertile areas for drug discovery with platform potential. In 2014, Christopher and Kezar co-founder John Fowler began developing the business plan for Kezar, acting on a longstanding desire to work together and build a world-class company. In 2015, John and Christopher raised $23M and negotiated a worldwide, exclusive license agreement with Amgen for the Onyx immunoproteasome inhibitor patent estate. Now underway, John and Christopher are excited to leverage their complementary skill sets to build Kezar into a leader in small molecule drug development.

arizonia infectious disease society

arizonia infectious disease society is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Orion Genomics

Orion Genomics is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.